cover image: Clinical and economic overview : Biological response modifier agents for adults with rheumatoid arthritis

Premium

20.500.12592/1035qn

Clinical and economic overview : Biological response modifier agents for adults with rheumatoid arthritis

30 Nov 2010

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada. [...] The clinical inputs for the economic evaluation were based on the results of the MTC meta-analyses, in which clinically meaningful differences in ACR between the biologic agents were not observed (Table 1). [...] MTX- X X X X X X X 8 2004. [...] MTX- X X X X X X X X experienced 30 Weinblatt et al. [...] MTX- X X X X X X X X experienced 35 GO-BEFORE 2009.
health cost-benefit analysis research drugs cancer medical research medicine health care tumor necrosis factor-alpha therapy clinical trial methotrexate arthritis, rheumatoid clinical medicine healthcare policy health treatment health sciences clinical government health care meta-analyses medical drugs medical specialties biopharmaceutical rheumatoid arthritis infliximab sensitivity analyses anakinra adalimumab antirheumatic agents tnf-alpha inhibitor tnf-alpha inhibitors
Pages
109
Published in
Canada

Related Topics

All